Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

NCT04907344 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

420

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Camrelizumab
DRUG: Nab-Paclitaxel
DRUG: Carboplatin

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]